Image

Global Disseminated Intravascular Coagulation (DIC) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Disseminated Intravascular Coagulation (DIC) Market, By Symptoms (Bleeding, Blood Clots, Bruising, Drop in Blood Pressure, Shortness of Breath, Confusion, Fever), Treatment (Medicines, Transfusions, Surgery, Others), Diagnosis (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Disseminated Intravascular Coagulation (DIC) Market

Market Analysis and Size

In recent years, the disseminated intravascular coagulation (DIC) market is anticipated to grow rapidly during the forecast period owing to the increasing prevalence of cancer. As per the International Agency for Research on Cancer (IARC), the global burden of cancer is anticipated to increase to 27.5 million new cases along with 16.3 million deaths by 2040. Cancer is one of the major risk factor that for disseminated intravascular coagulation (DIC). Disseminated intravascular coagulation (DIC) is a hazardous condition in which blood clotting proteins become hyperactive.

Data Bridge Market Research analyses that the disseminated intravascular coagulation (DIC) market was valued at USD 416.961 million in 2021 and is expected to reach USD 532.31 million by 2029, registering a CAGR of 3.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Disseminated intravascular coagulation (DIC) is a rare disorder which resulted in the occurrence of blood flow problems. It's a clotting problem that can lead to uncontrollable bleeding. About 10% of all persons with sepsis, diseases including cancer or pancreatitis, as well as people recovering from traumatic injuries involving burns or serious problems during pregnancy and delivery, are affected by DIC.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Symptoms (Bleeding, Blood Clots, Bruising, Drop in Blood Pressure, Shortness of Breath, Confusion, Fever), Treatment (Medicines, Transfusions, Surgery, Others), Diagnosis (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Hikma Pharmaceuticals PLC (UK), Fresenius Kabi AG (Germany), Eisai Co., Ltd. (Japan)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Disseminated intravascular coagulation (DIC) market Dynamics

Drivers

  • Increasing prevalence of cancer

The rising prevalence of cancer is a primary driver of the disseminated intravascular coagulation (DIC) market's growth. Along with this, blood transfusion reaction, pregnancy complications, inflammation of the pancreas, liver disease, and infection in the blood are the risk factors of DIC that will further influence the market dynamics during the forecast period.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of disseminated intravascular coagulation (DIC) market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the disseminated intravascular coagulation (DIC) market. Additionally, high disposable income and increasing incidences of severe tissue injury such as burns and head injury will result in the expansion of disseminated intravascular coagulation (DIC) market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the disseminated intravascular coagulation (DIC) market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the disseminated intravascular coagulation (DIC) market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of disseminated intravascular coagulation (DIC) will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the disseminated intravascular coagulation (DIC) market. Additionally, complications involved with disseminated intravascular coagulation (DIC) such as lack of blood flow to arms, legs, bleeding, stroke and others will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This disseminated intravascular coagulation (DIC) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the disseminated intravascular coagulation (DIC) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Disseminated intravascular coagulation (DIC) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Disseminated intravascular coagulation (DIC) market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of disseminated intravascular coagulation (DIC) in recent months.

Global disseminated intravascular coagulation (DIC) market Scope

The disseminated intravascular coagulation (DIC) market is segmented on the basis of symptoms, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

  • Bleeding
  • Blood Clots
  • Bruising
  • Drop in Blood Pressure
  • Shortness of Breath
  • Confusion
  • Fever

On the basis of symptoms, the disseminated intravascular coagulation (DIC) market is segmented into bleeding, blood clots, bruising, drop in blood pressure, shortness of breath, confusion, and fever.

Treatment

  • Medicines
  • Transfusions
  • Surgery
  • Others

Based on treatment, the disseminated intravascular coagulation (DIC) market is segmented into medicines, transfusions, surgery and others. The medication section is further categorized into antibiotics, heparin and antithrombin which may be used to help with coagulation problems.

Diagnosis

  • Complete Blood Count with Blood Smear Exam
  • Partial Thromboplastin Time (PTT)
  • Prothrombin Time (PT)
  • Fibrinogen Blood Test
  • D-dimer
  • Others

On the basis of diagnosis, the global disseminated intravascular coagulation (DIC) market is segmented into complete blood count with blood smear exam, partial thromboplastin time (PTT), prothrombin time (PT), fibrinogen blood test, D-dimer and others.

Route of Administration

The route of administration segment for the disseminated intravascular coagulation (DIC) market is segmented into oral, parenteral and others.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the disseminated intravascular coagulation (DIC) market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the disseminated intravascular coagulation (DIC) market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Disseminated intravascular coagulation (DIC) market Regional Analysis/Insights

The Disseminated intravascular coagulation (DIC) market is analysed and market size insights and trends are provided by country, symptoms, treatment, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Disseminated intravascular coagulation (DIC) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the disseminated intravascular coagulation (DIC) market because of the rising healthcare expenditure and adoption of advanced technologies in this region. Additionally, growing demand for advanced treatment options for this disease will further propel the market’s growth rate in this region.

Europe is expected to grow during the forecast period of 2022 to 2029 due to growing prevalence of disseminated intravascular coagulation (DIC) and growing focus of major key players on novel technology in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Disseminated Intravascular Coagulation (DIC) Market Share Analysis

The Disseminated intravascular coagulation (DIC) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to disseminated intravascular coagulation (DIC) market.

Some of the major players operating in the disseminated intravascular coagulation (DIC) market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • AstraZeneca (UK)
  • AbbVie Inc. (US)
  • Johnson & Johnson Private Limited (US)
  • Cipla Inc. (US)  
  • Abbott (US)
  • Merck KGaA (Germany)
  • Hikma Pharmaceuticals PLC (UK)
  • Fresenius Kabi AG (Germany)
  • Eisai Co., Ltd. (Japan)

Research Methodology: Global Disseminated Intravascular Coagulation (DIC) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for Disseminated Intravascular Coagulation (DIC) Market is expected USD 532.31 million by 2029.
The Disseminated Intravascular Coagulation (DIC) Market is to grow at a CAGR of 3.10% during the forecast by 2029
The expansion of the Global Disseminated Intravascular Coagulation (DIC) Market will be fueled by the rising prevalence of cancer and increasing incidences of severe tissue injury such as burns and head injury. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global disseminated intravascular coagulation (DIC) market.
The major players operating in the Disseminated Intravascular Coagulation (DIC) Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Hikma Pharmaceuticals PLC (UK), Fresenius Kabi AG (Germany), Eisai Co., Ltd. (Japan).